参考文献:
[1]黄峻,黄祖瑚。临床药物手册(第五版).上海科学技术出版社.
[2]中华医学会心血管病学分会心力衰竭学组.中国心力衰竭诊断和治疗指南2018.中华心血管病杂志.2018, 46(10)
[3]Theresa A McDonagh, Marco Metra, Marianna Adamo, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, ehab368, 27 August 2021.
[4]Vaduganathan, Muthiah, et al. "Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials." The Lancet (2020).
[5]John J V McMurray,et al.A trial to evaluate the effect of the sodium–glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction(DAPA-HF)[J].Eur J Heart Fail. 2019 May;21(5):665-675. doi: 10.1002/ejhf.1432. Epub 2019 Mar 21.